colonic biopsy. One hundred and sixty patients were entered into the programme and had 739 colonoscopies (4.6 colonoscopies per patient; 709 patient years follow up). Eighty eight per cent of examinations reached the right colon. There was no procedure related death. One Dukes's A cancer was detected. Forty one patients (25%) defaulted. Of these 25 remain well; 13 are unaccounted for, and one died from colonic cancer. One patient had colectomy for medical reasons, and another died of carcinoma of the pancreas. Retrospectively an additional 16 eligible patients were identified who had not been recruited. Of these, 14 remain well, two are unaccounted for. None developed colonic cancer. Four patients refused colonoscopy. All remain well. Over the same period seven other cases of colonic cancer were found in association with ulcerative colitis, two in patients who had erroneously been diagnosed as having only proctitis and were therefore not entered into the programme, but were found at operation to have total colitis, one in a patient with colitis of seven years duration, and four patients who had previously attended the clinic but had been lost to follow up before 1978 and then had represented with new symptoms during the surveillance period. Thus, of the nine colitis related cancers diagnosed in this centre during the study period only one was detected by the surveillance programme. The results of this large study, and a review of published works, cast doubts on the effectiveness of colonoscopic surveillance programmes in detecting colorectal cancer in patients with ulcerative colitis. (Gut 1993; 34: 1075-1080) Centre [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] later. One patient died of disseminated colonic cancer after three years (see Table  I , patient E), the three previous complete annual colonoscopies had been negative for dysplasia. One patient had colectomy for medical reasons six years later. No cancer was found. One patient died of pancreatic cancer seven years later.
LOW GRADE DYSPLASIA Forty patients were found to have low grade dysplasia in at least one biopsy. The mean age at first diagnosis of low grade dysplasia was 45 2 years (SD and mean duration of colitis to diagnosis of low grade dysplasia 17-7 years (SD 7 33) .
These 40 patients had a further 201 colonoscopies (223 patient years follow up). Twenty (50%) had no further dysplasia (mean 4 0 colonoscopies per patient over 4-7 years). Nineteen continued to exhibit low grade dysplasia in at least one subsequent biopsy (mean 6-3 follow up colonoscopies per patient over 6 9 years). One of There are no universally accepted entry criteria for cancer surveillance. [26] [27] [28] There is a general feeling in published studies that colitis extending beyond the splenic flexure can be regarded as extensive in terms of cancer risk.2 Assessment of extent, however, may be by barium enema, colonoscopy or both. Barium studies seem to be insensitive to microscopic involvement29 and may detect only more severe cases. In our study two patients were originally diagnosed as having proctitis. Ifcolonoscopy had been done the extensive nature of the disease might have been recognised and the patient would have entered the programme. Colitis for at least eight years is considered to be longstanding. In this series, however, one patient developed cancer after seven years disease duration so perhaps the criteria for entry should be widened.
Colonscopic surveillance programmes cause a heavy clinical workload as well as a substantial capital outlay'9 20 -that is, the test is not simple or cheap.
Patient recruitment is a recognised problem; 12% were not recruited into our programme. Some were lost to follow up from clinic before fulfilling the entry criteria for longstanding disease; others despite being eligible, were not entered. Once recruited, patients had a regular, uncomfortable examination that requires a day off work. In our study four patients refused colonoscopy, and 41 (27%) patients defaulted from the programme -strong evidence that annual colonoscopy is unacceptable to many.
There are problems with the discriminatory power of colonoscopy and biopsy. Colonic epithelial dysplasia is patchy.303' Multiple biopsies sample much less than 1% ofthe surface area of the colon. The evidence for the association of dysplasia and cancer is conflicting. All patients with ulcerative colitis should be screened at eight years. This will allow them to be assessed microscopically as 'total', 'extensive', or 'left sided' providing important information about their cancer risk. All patients with colitis should be followed up indefinitely. It is difficult to justify regular colonoscopy thereafter.
Clinicians faced with a patient with longstanding colitis, at increased risk ofdeveloping colonic cancer, feel compelled to do, or be seen to do, something. There is also an obligation, however, to use effective methods. The argument for colonoscopic surveillance is not convincing. While it has been deemed unethical to perform a controlled clinical trial, it could be argued that the use of limited resources on surveillance programmes of unproved value is also unethical. The funds released by ending surveillance are considerable. They could be channelled into a more cost effective cancer prevention scheme. It is time to review cancer surveillance in ulcerative colitis.
ulcerative colitis. 
Failure of colonoscopic surveillance in

